The unconjugated AM684 antibody has been evaluated by ELISA with trastuzumab deruxtecan and other DXd-conjugated ADC samples, and its binding to trastuzumab-Exatecan has been characterized by SPR. Cross-reactivity testing showed no detectable binding to ADCs carrying SN-38, MMAE, or DM1 payloads under the tested conditions. Biotinylated AM807 and HRP-conjugated AM684 have also been evaluated in ELISA formats for detecting trastuzumab deruxtecan.

ACROBiosystems Anti-DXd antibodies have been evaluated in target-capture ELISA configurations using trastuzumab deruxtecan in human serum. Data are available with unconjugated, biotinylated, and HRP-conjugated formats, including assays performed in 50% or 100% human serum. These results support assay feasibility, while calibration range, matrix effects, accuracy, and precision must be established for the intended bioanalytical method.

An Anti-DXd assay can measure payload-conjugated ADC remaining under defined conditions, but the signal alone does not directly establish the cause of any change. Linker stability assessment generally requires comparison with complementary analytes such as total antibody or released payload. ACROBiosystems Anti-DXd antibodies can provide the payload-specific measurement within this broader analytical assessment.

The unconjugated AM684 antibody provides flexibility for use as a capture reagent or with a separate secondary detection system. Biotinylated AM807 supports streptavidin-based detection, while HRP-conjugated AM684 enables direct enzymatic detection without an additional labeled secondary reagent. Selection should be based on the position of the Anti-DXd antibody in the assay and the required detection chemistry.

Anti-DXd binding alone indicates the presence of an accessible DXd-associated structure but does not fully define the molecular species being measured. To quantify payload-conjugated ADC, the assay must also capture or detect the antibody or target-binding component of the ADC. ACROBiosystems Anti-DXd antibodies can serve as the payload-specific component in such assay configurations.

DXD is an Exatecan derivative used as a cytotoxic payload in ADCs such as trastuzumab deruxtecan. Anti-DXd antibodies recognize the DXd-associated structure and can bind DXd presented within payload-conjugated ADCs. ACROBiosystems provides recombinant monoclonal Anti-DXd antibodies for incorporating this payload-specific recognition into immunoassays.